Heather McKenzie is a Senior Editor at BioSpace, specializing in the field of life sciences. With a keen interest in the latest advancements in biotechnology and pharmaceuticals, Heather covers topics related to drug development, gene therapy, FDA approvals, and emerging startups in the industry. Her articles provide insights into the ever-evolving landscape of the life sciences sector.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Heather's coverage is predominantly focused on the healthcare and pharmaceutical industry, with a specific emphasis on FDA approvals, gene therapy, CRISPR technology, drug development, Alzheimer's disease, and CNS diseases. Her articles heavily cite data and press releases.
Given Heather’s focus on citing data and press releases in her articles about healthcare and pharmaceuticals, she may be interested in receiving pitches from experts who can provide statistical analysis or insights based on solid scientific evidence related to these topics. Pitches offering access to exclusive data or early access to research findings could also be appealing.
Heather does not appear to have a specific geographic focus but rather seems to cover global developments within the healthcare and pharmaceutical industry.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Greg Slabodkin, Heather Mckenzie, Jef Akst, Annalee Armstrong
In our anniversary episode, we discuss a rare earnings miss for Eli Lilly, a pivotal metabolic dysfunction–associated steatohepatitis victory for Novo Nordisk’s Wegovy, growing excitement about CAR Ts for autoimmune disease and the ongoing controversy over HeLa cells.
Analyst reactions to Donald Trump’s election victory were mixed Wednesday, with potential positives including an FTC that is likely to be more friendly to M&A, and negatives including concerns about what role Robert F. Kennedy, Jr. might play in healthcare.
The Jacksonville Jaguars (2-7) host the Minnesota Vikings (6-2) in the EverBank Stadium at 1 p.m. today.
By: Jef Akst, Annalee Armstrong, Heather Mckenzie
A tale of two multi-billion schizophrenia deals, AstraZeneca touts strong sales while deflecting questions about an investigation into China exec, the Huntington’s pipeline builds momentum and layoffs continue with Sana Biotechnology and 23andMe.
By: Heather-Mckenzie
Following patient deaths in a lupus trial that led to the termination of that program, Kezar's autoimmune candidate zetomipzomib faces a partial clinical hold barring four trial participants from continuing treatment in the open-label portion of the trial, though the trial itself will continue as planned.
By: Heather Mckenzie
Eastside High School will face Bishop Moore High School for regional quarterfinals of the 3A FHSAA division tonight at 7:30 p.m.
Experts view BridgeBio’s acoramidis—which has an FDA action date of Nov. 29—as either similar to or incrementally better than Pfizer's already established tafamidis.
By: Heather Mckenzie
A handful of billion-dollar deals in the rare disease space highlights the uptick in Big Pharma’s investment, but it’s still extremely low compared to the money flowing to more common indications.
By: Heather-Mckenzie
Trump fingers Robert F. Kennedy Jr. to lead the HHS, lupus and ATTR-CM dominate headlines this week, bluebird bio has a cash gap to leap and RegenxBio eyes Sarepta in Duchenne muscular dystrophy.
The No. 23 Missouri Tigers will face the Mississippi State Bulldogs Saturday at 4:15 p.m.
(833) 317-6278 
